newsfilter
← Latest News
Business Wire·

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver